1. Home
  2. ARTL vs KTTA Comparison

ARTL vs KTTA Comparison

Compare ARTL & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • KTTA
  • Stock Information
  • Founded
  • ARTL 2011
  • KTTA 2020
  • Country
  • ARTL United States
  • KTTA United States
  • Employees
  • ARTL N/A
  • KTTA N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • KTTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTL Health Care
  • KTTA Health Care
  • Exchange
  • ARTL Nasdaq
  • KTTA Nasdaq
  • Market Cap
  • ARTL 3.1M
  • KTTA 2.8M
  • IPO Year
  • ARTL N/A
  • KTTA 2021
  • Fundamental
  • Price
  • ARTL $6.03
  • KTTA $0.78
  • Analyst Decision
  • ARTL Buy
  • KTTA
  • Analyst Count
  • ARTL 2
  • KTTA 0
  • Target Price
  • ARTL $30.00
  • KTTA N/A
  • AVG Volume (30 Days)
  • ARTL 13.2K
  • KTTA 286.6K
  • Earning Date
  • ARTL 08-12-2025
  • KTTA 08-12-2025
  • Dividend Yield
  • ARTL N/A
  • KTTA N/A
  • EPS Growth
  • ARTL N/A
  • KTTA N/A
  • EPS
  • ARTL N/A
  • KTTA N/A
  • Revenue
  • ARTL N/A
  • KTTA N/A
  • Revenue This Year
  • ARTL N/A
  • KTTA N/A
  • Revenue Next Year
  • ARTL N/A
  • KTTA N/A
  • P/E Ratio
  • ARTL N/A
  • KTTA N/A
  • Revenue Growth
  • ARTL N/A
  • KTTA N/A
  • 52 Week Low
  • ARTL $4.92
  • KTTA $0.71
  • 52 Week High
  • ARTL $9.30
  • KTTA $7.50
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 43.05
  • KTTA 33.17
  • Support Level
  • ARTL $6.20
  • KTTA $0.76
  • Resistance Level
  • ARTL $7.35
  • KTTA $0.83
  • Average True Range (ATR)
  • ARTL 0.45
  • KTTA 0.05
  • MACD
  • ARTL -0.09
  • KTTA 0.00
  • Stochastic Oscillator
  • ARTL 0.00
  • KTTA 20.41

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Share on Social Networks: